AstraZeneca doubles Lokelma output with $445m Texas plant expansion
The investment is part of AstraZeneca’s wider $50bn outlay to bolster manufacturing in the US.
Drug Manufacturers
BIOSECURE returns to US pharma agenda with 2.0 update
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
AstraZeneca sets $4.5bn Virginia API plant construction in motion
Halozyme eyes microparticles in $900m Elektrofi acquisition
Eli Lilly to build $6.5bn orforglipron production site in Texas
Eli Lilly picks Virginia for $5bn drug manufacturing plant
Opadry complete film coating system: 45 years of trust, innovation and performance
